Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users
| Autor: | Gerard Le Fur, Kenzie L. Preston, Marilyn A. Huestis, Stephen J. Heishman, Denis Bonnet, Susan J. Boyd, David A. Gorelick |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Adult
Male Drug Marijuana Abuse Time Factors Cannabinoid receptor media_common.quotation_subject medicine.medical_treatment Administration Oral Marijuana Smoking Pharmacology Multiple dosing Drug Administration Schedule Article Electrocardiography Sex Factors Double-Blind Method Piperidines Receptor Cannabinoid CB1 Rimonabant Heart Rate Tachycardia medicine Humans Dronabinol media_common Dose-Response Relationship Drug biology Antagonist biology.organism_classification nervous system Area Under Curve Pyrazoles lipids (amino acids peptides and proteins) Cannabis Cannabinoid Psychology medicine.drug |
| Zdroj: | Psychopharmacology. 194:505-515 |
| ISSN: | 1432-2072 0033-3158 |
| Popis: | A single 90-mg dose of the cannabinoid CB1 receptor antagonist rimonabant attenuates effects of smoked cannabis in humans.The objective of this study is to evaluate whether repeated daily 40-mg doses of rimonabant can attenuate effects of smoked cannabis to the same extent as a single higher (90 mg) dose.Forty-two male volunteers received one of three oral drug regimens in a randomized, double blind, parallel group design: (1) 40 mg rimonabant daily for 15 days, (2) placebo for 14 days, then 90 mg rimonabant on day 15, or (3) placebo for 15 days. All participants smoked an active or placebo cannabis cigarette 2 h after medication on days 8 and 15. Subjective effects were measured with visual analog scales and the marijuana-scale of the Addiction Research Center Inventory.Cannabis-induced tachycardia was significantly lower for the 40-mg group on day 8 and for the 40 and 90 mg rimonabant groups on day 15 as compared to placebo. The 40-mg dose significantly decreased peak subjective effects on day 8. Neither the 90-mg nor 40-mg doses significantly decreased peak subjective effects on day 15. Rimonabant treatment did not significantly affect Delta(9)-tetrahydrocannabinnol pharmacokinetics.Repeated lower daily rimonabant doses (40 mg) attenuated the acute physiological effects of smoked cannabis to a similar degree as a single 90-mg dose; repeated 40-mg doses attenuated subjective effects after 8 but not 15 days. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|